Texas will move to NADAC-based reimbursement methodology

Yesterday at the Medicaid Drug Rebate Program in Chicago, Andy Vasquez, Deputy Director of Texas' Medicaid/CHIP Vendor Drug Program shared that Texas will move to an NADAC-based reimbursement methodology. The state will no longer participate in monthly reporting of drug numbers - which will ,most likely be eliminated sometime in 2015. As for prices, where there is no NADAC published price for a drug, WAC will be set at - 2%. However, new drug applications will still have to be submitted to the NADAC program for product integration in to the system as well as to identify prices at the launch of the drug.